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Abstract 
Background: The endometrial regenerative cell (ERC) is a novel type of adult mesenchymal stem cell isolated from 
menstrual blood. Previous studies demonstrated that ERCs possess unique immunoregulatory properties in vitro and 
in vivo, as well as the ability to differentiate into functional hepatocyte-like cells. For these reasons, the present study 
was undertaken to explore the effects of ERCs on carbon tetrachloride (CCl4)–induced acute liver injury (ALI).
Methods: An ALI model in C57BL/6 mice was induced by administration of intraperitoneal injection of CCl4. Trans-
planted ERCs were intravenously injected (1 million/mouse) into mice 30 min after ALI induction. Liver function, 
pathological and immunohistological changes, cell tracking, immune cell populations and cytokine profiles were 
assessed 24 h after the CCl4 induction.
Results: ERC treatment effectively decreased the CCl4-induced elevation of serum alanine aminotransferase (ALT) 
and aspartate aminotransferase (AST) activities and improved hepatic histopathological abnormalities compared 
to the untreated ALI group. Immunohistochemical staining showed that over-expression of lymphocyte antigen 6 
complex, locus G (Ly6G) was markedly inhibited, whereas expression of proliferating cell nuclear antigen (PCNA) was 
increased after ERC treatment. Furthermore, the frequency of CD4+ and CD8+ T cell populations in the spleen was 
significantly down-regulated, while the percentage of splenic CD4+CD25+FOXP3+ regulatory T cells (Tregs) was obvi-
ously up-regulated after ERC treatment. Moreover, splenic dendritic cells in ERC-treated mice exhibited dramatically 
decreased MHC-II expression. Cell tracking studies showed that transplanted PKH26-labeled ERCs engrafted to lung, 
spleen and injured liver. Compared to untreated controls, mice treated with ERCs had lower levels of IL-1β, IL-6, and 
TNF-α but higher level of IL-10 in both serum and liver.
Conclusions: Human ERCs protect the liver from acute injury in mice through hepatocyte proliferation promotion, as 
well as through anti-inflammatory and immunoregulatory effects.
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Background
Despite unprecedented advances made in modern 
medicine, acute liver diseases remain a healthcare bur-
den. They can arise from viral infections, autoimmune 
disorders, ischemia, and xenobiotics such as alcohol, 
drugs and toxins, and can lead to severe clinical out-
comes including hepatorenal syndrome, hepatic enceph-
alopathy, severe infection, multiple organ failure, and 
even death [1]. To date, orthotropic liver transplantation 
is the most effective therapeutic option for patients suf-
fering from severe irreversible and life-threatening liver 
damage; however, the limited availability of donor organs, 
high costs, and lifelong immunosuppressive therapy has 
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alternative strategies for the treatment of decompensated 
liver diseases are required.
Recent development in stem cell-based therapeutic 
strategies have already garnered extensive attention and 
been introduced to regenerative medicine for hepatic 
diseases [3–5]. It has been demonstrated that infused 
mesenchymal stem cells (MSCs) engrafting in the liver 
facilitate the recovery from chemical-induced acute 
liver damage [6]. Moreover, MSCs possess the charac-
teristics of immunomodulatory, anti-inflammatory and 
hypoimmunogenicity, and the potential of differentiat-
ing into hepatocyte-like cells. Also, MSCs can promote 
tissue repair by means of suppressing the local immune 
reaction, attenuating fibrosis and apoptosis, enhancing 
angiogenesis and stimulating mitosis and differentiation 
of tissue-intrinsic reparative cells and stem cells [7, 8]. 
Currently, bone marrow mesenchymal stem cells (BM-
MSCs) have become the focal point for cell therapy in 
liver regeneration [9, 10]. However, BM-MSCs have low 
yield, invasive operation and decreased cell numbers 
that are dependent on donor age [11]. Consequently, it 
is imperative to identify alternative sources of stem cells 
with better safety and efficacy profiles.
In 2007, Meng et  al. discovered a novel type of adult 
stem cells derived from human menstrual blood, named 
endometrial regenerative cells (ERCs). These cells pos-
sess a self-renewing, highly proliferative potential as well 
as a differentiation capacity towards diverse cell lineages 
in appropriate induction media, thereby overcoming the 
shortcomings of other conventional stem cell sources and 
the fear of karyotypic abnormalities during culture [12]. 
Furthermore, ERCs have proven to be an excellent cell 
source in the treatment of several experimental disease 
models, such as critical limb ischemia [13], ulcerative 
colitis [14], burn injury [15], renal ischemia reperfusion 
injury [16] and other dysfunctional diseases [17–19]. 
Moreover, it has been verified that these human cells 
were not rejected in a xenogeneic animal model [13]. 
ERCs are more readily available and non-invasive than 
other adult stem cells, making them a promising donor 
source for stem cell therapy. Recently, ERCs were found 
to be capable of differentiating into functional hepato-
cyte-like cells in vitro [20]. However, whether ERCs could 
simultaneously suppress inflammatory and immune 
responses and repair tissue damage following ALI remain 
obscure. Thus, the aim of this study was to explore the 




ERCs were collected from the menstrual blood of healthy 
female volunteer donors (20–40 years old) using a urine 
cup after menstrual blood flow initiated. As previously 
described [12], mononuclear cells were obtained by 
standard Ficoll method. ERCs were then expanded from 
the purified mononuclear cells, which were allowed 
to attach in the endometrial stem cell culture medium 
(S-Evans Biosciences, China) overnight at 37  °C in 5  % 
CO2. Non-adherent cells were removed by washing with 
phosphate-buffered saline (PBS), while adherent cells 
were cultured until they reached 80–90  % confluence. 
Cells were trypsinized, sub-cultured and used for experi-
ments during passages 4–7.
Animals
Healthy male C57BL/6 mice (Aoyide Co., Tianjin,China) 
weighing 18–20  g and aged 6–8  weeks were housed 
under conventional experimental environment with 12-h 
light–dark cycle in the Animal Care Facility, Tianjin Gen-
eral Surgery Institute. The mice had free access to com-
mercial standard mouse diet and water until the time of 
the study. All experiments were conducted in accordance 
with the protocols following the Animal Care and Use 
Committee of Tianjin Medical University (China) accord-
ing to the Chinese Council on Animal Care guidelines.
Experimental groups
The preparation of animal model was done as previ-
ously described [21, 22]. In brief, 18 mice were randomly 
assigned to the following three groups (n = 6). (1) Nor-
mal control group: mice first receiving intraperitoneal 
(i.p.) injection of corn oil were then injected with 200 μl 
PBS intravenously 30  min later. (2) Untreated group: 
mice first receiving i.p. injection of a single dose of CCl4 
(Sigma-aldrich, St Louis, United States) for induction of 
acute liver injury were injected 200 μl PBS intravenously 
30 min later. (3) ERC-treated group: mice first receiving 
i.p. injection of CCl4 were injected intravenously with 
1 × 106 ERCs at passage 4 resuspended in 200 μl of PBS 
30  min later [23]. Mice were sacrificed 24  h after injec-
tion of CCl4, and blood was collected. Livers and spleens 
were then promptly removed for analysis or stored frozen 
at −80 °C.
Measurement of ALT and AST
Serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) activities were measured by 
standard spectrophotometric procedures using a Chemi-
Lab ALT and AST assay kit (IVDLab Co., Ltd., Korea), 
respectively. Enzyme activities were shown in interna-
tional unit per liter (IU/L).
Histological examination
Liver slices were made from part of the left lobes and 
fixed in 10  % neutral buffered formalin, embedded in 
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paraffin and cut into 5  μm sections. Specimens were 
dewaxed, hydrated and stained with standard hematoxy-
lin and eosin (H&E) to examine morphology.
Immunohistochemistry staining
Immunohistochemistry was performed with PCNA 
and Ly6G antibody as described previously [24]. Briefly, 
the paraffin specimens were cut into 5  μm, followed by 
deparaffinization and rehydration. Endogenous peroxides 
were eliminated with 3 % H2O2, and antigen retrieval was 
processed by heating in microwave. Then, the sections 
were blocked with 5 % bovine serum albumin (BSA) and 
incubated with anti-mouse PCNA and Ly6G (Abcam, 
Cambridge, MA) antibodies overnight at 4  °C, respec-
tively. Secondary labeling was achieved by goat anti-
rabbit IgG and rabbit anti-rat IgG polyclonal antibody, 
separately. Horseradish peroxidase-conjugated avidin 
and brown-colored diaminobenzidine were used to visu-
alize the labeling. Finally, the slides were counterstained 
with hematoxylin. All of stained sections were photo-
graphed using an Olympus inverted microscope (Olym-
pus Imaging America, Center Valley, PA).
Enzyme‑linked immunosorbent assay
The levels of IL-1β, IL-6, TNF-α,and IL-10 in the serum 
and liver samples taken from mice 24 h after CCl4 challenge 
were measured by ELISA kit (eBiosciences, San Diego, CA, 
USA) according to the manufacturer’s instructions. ELISA 
was performed in duplicate for each sample. The prepara-
tion of liver homogenate was done as previously described 
[25]. In short, frozen liver tissues were homogenized in a 
protein extraction solution (PRO-PREP; Intron biotech-
nology, Sungnam, Korea), incubated for 30 min on ice and 
then centrifuged at 13,000 rpm (4 °C) for 10 min.
Flow cytometry analysis
The phenotype of various immune cells was evaluated 
by flow cytometry analysis [FACS, Epic XL, Software 
Expo32 (Beckman coulter)]. Briefly, splenocytes were 
stained with fluoresent antibodies, including anti-CD3ε-
FITC, anti-CD8a-PerCP, anti-CD4-PE/FITC, anti-CD25-
PE, anti-Foxp3-PerCP, anti-CD11c-PE, anti-MHCII-FITC 
(eBiosciences, San Diego, CA, USA), according to the 
manufacturer’s instructions. The percentage of each 
phenotype of immune cells was analyzed with the corre-
sponding Flowjo software.
Labeling of ERCs with PKH26 and in vivo tracking
For in  vivo tracking of administered ERCs, cells were 
isolated and labeled with PKH26 Red Fluorescent Cell 
Linker Kits (Sigma-aldrich, St Louis, USA), according to 
the manufacturer’s instructions. Prepared PKH26-labeled 
ERCs at a final cell concentration of 1 × 107 cells/ml were 
then injected via tail vein 30  min after ALI induction. 
Mice were executed 24 h later, and the liver, lung, kidney 
and spleen were removed and frozen at −20 °C. Fluores-
cence microscopy was performed to analyze the 4  µm 
cryosections and identify the ERCs.
Statistical analysis
All the experimental data were presented as 
mean ±  standard error of the mean (SEM). The results 
were statistically analyzed by ANOVA test utilizing SPSS 
version 17.0 software (SPSS Inc., Chicago, USA). p < 0.05 
was considered statistically significant.
Results
ERC treatment improved liver function after ALI
The serum levels of ALT and AST in the untreated group 
were markedly increased after CCl4 injection compared 
with the normal control group (p  <  0.01; Fig.  1a, b). In 
contrast, both serum levels of ALT and AST were sig-
nificantly decreased by ERC treatment (p  <  0.01), even 
though they were still higher than those of normal con-
trol group (Fig. 1a, b, p < 0.05). In addition, we also found 
that serum ALT and AST rapidly elevated to peak level 
24  h after CCl4 treatment, then decreased thereafter, 
while ERC treatment significantly inhibited the eleva-
tion of serum ALT and AST from 24 to 120 h (Data not 
shown). Taken together, these data suggested that ERCs 
improve liver function in mice with ALI.
ERCs ameliorated the histopathological damage of liver 
tissue after acute injury
As shown in Fig. 2, in the untreated ALI group, the liver 
became inflamed, turned yellowish-white, and increased 
in volume at 24 h after CCl4 injection (Fig. 2a), suggest-
ing that CCl4 had induced severe liver cell injury. Nota-
bly, the changes observed in the ERC-treated livers were 
indistinguishable from those in the normal control group 
(Fig.  2a). In addition, degeneration of liver structure 
and pathological changes of hepatic parenchymal cells 
were observed in CCl4-induced mice, characterized by 
hepatocyte necrosis, shrinkage of nuclei, and infiltration 
of inflammatory cells in the portal area (Fig. 2b). In con-
trast, all these abnormal changes were alleviated at the 
same time point after ERC treatment (Fig. 2b). The gross 
findings and the pathological changes of the liver tissue 
in ERC-treated group were similar to those of normal 
controls (Fig.  2a, b). Meanwhile, in consistent with the 
results of liver function study, we found that the patho-
logical changes of the liver tissue in untreated group at 
48, 72, and 120 h time points could be reversed by ERC 
infusion (Data not shown). Overall, these results indi-
cated that ERC treatment could effectively protect the 
liver from CCl4-induced acute liver damage.
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Fig. 1 ERCs improved liver function in CCl4-induced ALI mice. Serum samples were collected from mice of the normal control, untreated and ERC-
treated groups. ERCs significantly reduced serum levels of a ALT and b AST in comparison with those of untreated ALI group. Bar graphs represent 
mean ± SEM of three separate experiments. p values were determined by one-way ANOVA. Data show are representative of three separate experi-
ments performed. (##p < 0.01 versus the normal control group. *p < 0.05, **p < 0.01 versus the untreated group, n = 6)
Fig. 2 ERC treatment markedly attenuated histopathological damage after CCl4 induction. Mice were treated with CCl4 (1 ml/kg body weight and 
1:3 diluted in corn oil) to induce acute liver injury, then intravenously administered with ERCs (1 × 106/0.2 ml/mouse, suspended in PBS) 30 min 
after CCl4 injection, only once in 24 h. Photographs of livers were taken 24 h after CCl4 injection. a indicates gross pathological changes of livers. b 
Representative photomicrographs of histological sections of liver (200×, haemotoxylin and eosin staining). Livers in the untreated group exhibited 
more ballooned hepatocytes, apoptosis and necrosis than those in the normal control groups, which were significantly alleviated by ERC treatment 
(n = 6)
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ERC infusion promoted hepatocyte proliferation in mice 
with ALI
To determine whether ERCs have a role in accelerating 
hepatocyte proliferation after ALI, PCNA expression was 
detected in the liver tissue by immunohistochemistry. As 
shown in Fig. 3, compared to the untreated group, ERC 
infusion dramatically increased the number of PCNA 
positive-staining cells at 24 h after CCl4 induction, with a 
great number of PCNA positive hepatocytes surrounding 
the portal area. The changes are indistinguishable from 
those in the normal control group. This finding demon-
strated that treatment with ERCs may markedly promote 
liver cell proliferation after CCl4-induced ALI.
ERC treatment inhibited neutrophil infiltration in the liver 
after ALI
To characterize whether ERC treatment could prevent 
inflammatory cell infiltration following ALI, we per-
formed immunohistochemical staining to evaluate the 
recruitment of neutrophils in liver tissue. As shown in 
Fig.  3, ERC treatment notably reduced the number of 
Ly6G positive cells in the liver compared to those without 
ERC administration. These results suggested that ERCs 
significantly reduced neutrophil infiltration in the liver 
caused by acute liver damage.
ERC treatment attenuated ALI by regulating cytokine 
expression
To determine whether ERC treatment could affect 
cytokine profiles, the levels of local and systemic inflam-
matory cytokines were analyzed and compared among 
different groups. As shown in Fig. 4, compared with the 
normal control group, the untreated group exhibited sig-
nificantly higher levels of pro-inflammatory cytokines 
(IL-1β, IL-6 and TNF-α) in both the liver (p < 0.01) and 
the serum (p  <  0.01). In contrast, these cytokine levels 
were markedly reduced in ERC-treated group (p < 0.01, 
versus untreated group). On the other hand, the level of 
anti-inflammatory cytokine IL-10 was notably elevated 
after ERC treatment (p  <  0.01, versus untreated group). 
Taken together, these data suggested that treatment with 
ERCs not only suppress the level of pro-inflammatory 
cytokines, but also enhance the level of anti-inflamma-
tory cytokine in CCl4-induced ALI mice.
ERC treatment decreased the percentage of CD11c+MHCII+ 
cells in the spleen after ALI
Recently Zhang et al. and Nauta et al. demonstrated that 
MSCs derived from different human tissues reduced the 
expression of presentation molecules (MHC class II) and 
co-stimulatory molecules (CD80 and CD86) on mature 
dendritic cells (DCs) [26, 27]. In this regard, we investi-
gated whether ERC treatment could affect the population 
of antigen-presenting cells in ALI mice. As shown in 
Fig. 5, the frequency of MHCII positive DCs in the spleen 
was significantly lower in ERC-treated mice compared 
to untreated mice (p < 0.01), which suggested that ERC 
treatment could reduce the population of mature DCs.
ERCs influenced the populations of CD3+CD4+ 
and CD3+CD8+ T cells in ALI mice
To study the relationship between the changes of T 
cell population and ERC-mediated liver protection, 
we employed flow cytometric analysis to detect the 
levels of CD3+CD4+ and CD3+CD8+ T cells in both 
spleen and liver. As indicated in Fig.  6, the percentages 
of CD3+CD4+ and CD3+CD8+ T cells in the spleen 
were dramatically decreased as compared with those 
of untreated mice (Fig. 6, p < 0.01). However, no differ-
ence was observed in the percentages of CD3+CD4+ and 
CD3+CD8+ in the liver in all groups (data not shown).
ERC treatment upregulated splenic Treg population in ALI 
mice
To further investigate the immunomodulatory func-
tion of ERCs in the attenuation of ALI, we measured 
and compared splenic Treg population among different 
groups. The percentage of Tregs in the untreated group 
was much lower than that of the normal control 
group (Fig.  7, p  <  0.01). In contrast, the percentage of 
CD4+CD25+Foxp3+Treg population was significantly 
increased by ERC treatment in ALI mice (Fig. 7, p < 0.01, 
versus untreated group and normal control group), dem-
onstrating that ERCs have hepato-protective effects in 
CCl4-induced acute liver injury through upregulation of 
Treg population in mice.
Tracking in vivo engraftment of ERCs
To investigate whether PHK26-ERCs are capable of 
engrafting CCl4-injured liver, animals were sacrificed 
24  h after CCl4 induction. As shown in Fig.  8, PHK26-
positive ERCs were detected by fluorescence microscopy 
in the liver (injured tissue) and the spleen (lymphoid 
organ) of ERC-treated mice. Moreover, the labeled ERCs 
were aslo mainly found in the lung, but not in other nor-
mal organs, such as the kidney.
Discussion
Liver failure can be caused by acute severe or chronic 
persistent liver injury, while effective treatment are still 
scarce. Considering the current clinical state, developing 
an alternative therapeutic strategy to reduce damage, pre-
vent progression, and restore liver function is warranted. 
Several reports have described the safety and promis-
ing beneficial effects of MSCs in the treatment of acute 
liver injury [6, 28]. However, the value of ERCs, a novel 
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type of MSCs obtained from menstrual blood, in ALI 
has not been studied. Compared with MSCs from other 
sources, ERCs have several additional outstanding mer-
its, such as (1) abundant availability, (2) easy and non-
invasive acquisition and separation method, (3) higher 
proliferative rate, (4) relatively unlimited expandability 
without karyotypic or functional abnormality, (5) more 
multi-lineage differentiation capacities [29]. In this study, 
we observed that ERC therapy is an effective strategy for 
alleviation of ALI. We mainly focused on investigating 
the therapeutic potential of ERCs related to anti-inflam-
mation, immunomodulation, promotion of hepatocyte 
(See figure on previce page.) 
Fig. 3 ERCs promoted hepatic cell proliferation and suppressed inflammatory cell infiltration after CCl4 injury. Immunohistochemical staining for 
PCNA and Ly6G were carried out as previous described. PCNA and Ly6G staining of liver sections in the mice with or without ERC administration 
were performed 24 h after CCl4 treatment. The untreated group showed relatively few PCNA
+ hepatocytes and abundant Ly6G+ cells in centrilobu-
lar areas. Sections from ERCs treated group exhibited numerous PCNA+ hepatocytes surrounding the edge of hepatocellular necrosis and fewer 
inflammatory cell accumulating in liver tissues. The numbers of PCNA+ and Ly6G+ cells in the liver sections were measured. At least six 12 mm2 tis-
sue sections were counted for each mouse. Values represent mean ± SEM. (##p < 0.01 versus the normal control group. *p < 0.05, **p < 0.01 versus 
the untreated group, n = 6). (Magnification 100×)
Fig. 4 Treatment with ERCs diminished ALI by regulating cytokine profiles. The levels of IL-1β, IL-6, TNF-α,and IL-10 in sera and liver tissues were 
detected by ELISA at indicated time points after CCl4 challenge. Data indicated that ERC treatment significantly decreased the levels of a IL-1β, b 
IL-6,and c TNF-α, while increased the level of d IL-10 in CCl4-induced ALI. Values represent mean ± SEM. (##p < 0.01 versus the normal control group. 
*p < 0.05, **p < 0.01 versus the untreated group, n = 6)
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proliferation, as well as their engraftment after ERC 
infusion.
In the present study, we took the advantage of the 
mouse ALI model to mimic clinical liver dysfunction 
for evaluating the efficacy of ERC treatment. The mice 
exposed to CCl4 showed significant increase of ALT and 
AST, which were reduced by ERCs from an early phase 
of liver injury. Furthermore, livers of the untreated group 
became inflamed, turned yellowish-white, and increased 
in volume at 24  h after CCl4 injection, suggesting that 
CCl4 had induced severe liver cell injury. Notably, the 
changes of gross findings observed in ERC-treated livers 
were indistinguishable from those in the normal control 
group. In accordance with this finding, the histopatholog-
ical results demonstrated that ERC administration prom-
inently alleviated cytoplasmic vacuolization, necrosis and 
infiltration of inflammatory cells. Furthermore, to clarify 
if the similar beneficial effects of ERC injection be seen 
longer term, the effects of ERC infusion at different time 
points have also been studied. The results of biochemical 
assays and histological examination showed that similar 
beneficial effects could still be observed 2, 3 and 5 days 
after ALI induction. Meanwhile, ERCs could still provide 
a similar benefit when infused 2  h after ALI as 30  min 
after induction. Taken together, ERCs exhibited liver pro-
tective effects on this model of liver damage.
Accumulating evidences indicate that hepatocyte 
proliferation in stem cell therapy is closely related to 
increased expression of endogenous and exogenous 
trophic molecules, including growth factors, transform-
ing growth factor, vascular endothelial growth factor and 
so on [30]. Similar mechanisms have been reported in 
Fig. 5 ERCs alleviated ALI by modulating the frequency of DCs. Flow cytometric analysis of splenic DC population was performed in the normal 
control, untreated and ERC-treated groups. ERC treatment dramaticlly lowered the frequency of CD11c+MHCII+ cells in ALI mice compared with 
those of untreated ALI mice. Bar graphs represent mean ± SEM of three separate experiments. p values were determined by one-way ANOVA. Data 
show are representative of three separate experiments performed. (##p < 0.01 versus the normal control group. *p < 0.05, **p < 0.01 versus the 
untreated group, n = 6)
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Fig. 6 ERCs inhibited the frequency of CD4+ and CD8+ T cell populations in the spleen. a Flow cytometric analysis of CD3+CD4+ and CD3+CD8+ 
T cell populations was performed in the spleen of the normal control, untreated and ERC-treated groups. b ERC treatment dramaticlly reduced the 
percentages of CD3+CD4+ and CD3+CD8+ T cells in the spleen. Bar graphs represent mean ± SEM of three separate experiments. p values were 
determined by one-way ANOVA. Data show are representative of three separate experiments performed. (##p < 0.01 versus the normal control 
group. *p < 0.05, **p < 0.01 versus the untreated group, n = 6)
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acute kidney failure and stroke models [31, 32]. In addi-
tion, some in  vitro studies also proved that ERCs could 
differentiate into functional hepatocyte-like cells [13, 
33]. To determine the effect of ERCs on liver cell prolif-
eration, we performed PCNA immunohistochemistry. It 
was found that the population of PCNA positive cells was 
significantly higher in the ERC-treated group than that of 
the untreated group, demonstrating that ERCs could pro-
mote hepatocyte proliferation.
Neutrophils, a type of phagocytic cell, are potent 
immune regulators which play an important role in the 
inflammatory response [34]. Neutrophils have been 
implicated in several liver injury models such as alco-
holic hepatitis [35], ischemia/reperfusion injury of the 
liver [36], and concanavalin A-induced liver injury [37]. 
In  vivo studies have also exhibited that pathological 
changes in ALI are significantly improved in neutro-
phil-depleted mice [36, 38]. Our study demonstrated 
that ERCs could significantly reduce the numbers of 
Ly6G-positive cells in the liver compared to that of the 
untreated group. Therefore, we speculated that ERC 
treatment contributed to alleviating hepatocellular dam-
age against CCl4-induced ALI by suppressing inflamma-
tory cell infiltration.
Fig. 7 ERCs alleviated ALI by modulating the frequency of Treg population. Flow cytometric analysis of splenic CD4+CD25+FOXP3+Treg popula-
tion was performed in the normal control, untreated and ERC-treated groups. ERC treatment dramaticlly increase the percentage of Tregs in ALI 
mice compared with those of untreated ALI mice. Bar graphs represent mean ± SEM of three separate experiments. p values were determined by 
one-way ANOVA. Data show are representative of three separate experiments performed. (##p < 0.01 versus the normal control group. *p < 0.05, 
**p < 0.01 versus the untreated group, n = 6)
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Fig. 8 In vivo tracking of PKH26-labeled ERCs in CCl4-induced ALI. Frozen section of lung, liver, spleen and kidney from mice of the untreated (as 
control) and ERC-treated groups 24 h after CCl4 induction are showed. The strong red flourescent signals indicated that PKH26-positive cells were 
widely distributed in the hepatic lobules as scattered individual cells 24 h after ALI. Representative image showing PKH26-labeled ERCs were simul-
taneously observed in murine lung and spleen but not kidney. In addition, no obvious strong red flourescent signals were observed in the lung, 
liver, spleen or kidney from the untreated group (magnification ×100)
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Local down-regulation of pro-inflammatory cytokines 
and up-regulation of anti-inflammatory cytokines after 
MSC transplantation have been described in kidney, 
lung and liver injury models [31, 39, 40]. To address 
whether ERCs share the similar attributes in amelio-
ration of liver damage partially through regulating 
cytokine profiles in the ALI model, we measured the 
local and serum levels of cytokines. Our data showed 
that treatment with ERCs dramatically reduced the lev-
els of pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) 
and increased IL-10, and anti-inflammatory cytokine, 
compared to those of untreated mice. It has been known 
that the three acute-phase proteins, IL-1β, IL-6, and 
TNF-α, are tightly associated with inflammation and 
cell proliferation and viewed as biomarkers that reflect 
inflammatory conditions [41]. IL-1β has been previously 
shown to hamper hepatocyte proliferation [42, 43]. 
Both IL-1β and IL-1R-deficient mice were not sensi-
tive to inflammatory conditions at the acute phase [44]. 
IL-6 and TNF-α have also been identified as attractive 
targets for initiation and progression of liver regenera-
tion. Increasing evidence has shown that IL-6 hyper-
stimulation is more likely to cause liver injury [45, 46]. 
In another study, it was found that ischemia-induced 
renal damage was ameliorated in IL-6 knockout mice 
[47]. TNF-α, produced by Kupffer cells (macrophages 
in liver), acts as a pro-inflammatory mediator in liver 
apoptosis closely related with cytotoxicity induced by 
CCl4 [48, 49]. Okajima et  al. discovered that pretreat-
ment with anti-rat TNF-α antibody could significantly 
inhibit hepatic I/R [50]. In the current study, the levels 
of all these three cytokines were reduced by ERC treat-
ment, indicating that ERCs may directly inhibit the 
pro-inflammatory cytokine secretion to exert liver pro-
tective effects.
Meanwhile, previous studies reported that MSCs 
could secrete IL-10 directly and promote the produc-
tion of IL-10 by other antigen-presenting cells to exert 
anti-inflammatory and immunomodulatory effects [51, 
52]. It was claimed that IL-10 has a protective function 
in the liver injury animal model [53]. IL-10 negatively 
regulates liver regeneration by suppressing production of 
pro-inflammatory cytokines and inhibiting macrophage 
and neutrophil recruitment in hepatocytes [54]. The liver 
protective effect was abolished in IL-10-deficient mice 
and administration of recombinant IL-10 rescued these 
mice from chemical-induced hepatitis [25, 51]. In the 
present study, the levels of IL-10 in the liver and serum 
were elevated by ERC treatment, suggesting that ERCs 
may protect the mice from ALI by up-regulating IL-10 
both locally and systematically.
Previous studies demonstrated MSCs preferentially 
integrated into injured liver and enhanced hepatocyte 
regeneration when infused into CCl4 injured mice [28, 55, 
56]. Similarly, we transplanted xenogeneic PHK26-ERCs 
via intravenous injection and found that the transplanted 
human ERCs quickly migrated into the liver lobules in 
mice and could be visualized as scattered individual cells 
24 h after CCl4 administration. Additionally, the level of 
PCNA positive cells was significantly enhanced after ERC 
infusion, implying that human ERCs can migrate into the 
liver and promote liver regeneration in this ALI model. 
This notion is supported by previous studies that thera-
peutic effects of ERCs were observed despite utilization 
of human cells in an immuno-competent xenogeneic ani-
mal [13]. Thus, we speculated that ERCs may contribute 
to hepatocyte proliferation within this damaged environ-
ment. In the current study we have also confirmed that 
ERCs mainly accumulate in the lungs within 24  h after 
intravenous infusion. This is in accordance with earlier 
findings that the exogenous fluorescently labelled MSCs 
remained viable in the lungs up to 24  h after injection 
[57]. Notably, more fluorescently marked cells were also 
found in the spleen. Accordingly, the populations of 
immune cells in spleen were studied to explore the rela-
tionship between ERCs and systemic immune reaction.
Dendritic cells (DCs) are the principal antigen-pre-
senting cells in lymphoid organs and periphery includ-
ing the liver, and are key mediators for the initiation and 
regulation of both innate and adaptive immune responses 
[58, 59]. It has been reported that DCs exhibit fibrolytic 
properties, and the depletion of CD11c+ cells in the 
CCl4–induced liver  fibrosis model led to slower fibrosis 
regression and reduced clearance of activated hepatic 
stellate cells. Conversely, DC expansion induced either 
by Flt3L (fms-like tyrosine kinase-3 ligand) or adoptive 
transfer of purified DCs accelerates liver fibrosis regres-
sion [60]. In the current study, we evaluated the number 
of splenic DCs distant from the liver, and observed that 
the elevation of CD11c+MHC-II+ DC population after 
CCl4 challenge was significantly reduced by ERC treat-
ment. This is consistent with the finding that MSCs are 
capable of inhibiting the differentiation of monocytes 
into DCs [26, 27], suggesting that ERCs probably exert 
immunomodulatory effects on DCs to control the devel-
opment of ALI.
T lymphocyte subsets, including CD4+ and CD8+ T 
cells, play an important role in the pathogenesis of liver 
disease [61, 62]. However, the effect of CD4+ and CD8+ 
T cells on CCl4-induced acute hepatotoxicity in mice 
remains scarce and even controversial. According to pre-
vious studies, antigen-specific CD8+ T cells migrate to 
the contact site upon re-exposure to the chemicals and 
cause tissue damage through the release of cytokines 
and cytolytic molecules [63–66]. Researchers used an 
anti-CD8 monoclonal antibody to neutralized CD8 T 
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cells and demonstrated that depletion of CD8 T cells 
protected mice from Amodiaquine-induced liver injury 
[67]. Results from other experiments confirmed that 
CD4+ T cell depletion was capable of ameliorating the 
extent of injury with less neutrophil infiltration after I/R 
liver damage; however, liver damage was reproduced 
when adoptive transfer  of  CD4+ lymphocytes to CD4 
knockout mice [68, 69]. In our study, as compared with 
the untreated ALI group, ERC treatment group experi-
enced a significant reduction in CD4+ and CD8+ T cells, 
indicating that ERCs may inhibit T cell accumulation. 
The findings suggested that ERCs may have regulatory 
functions on the cell populations of splenic CD4+ and 
CD8+ T cells. Similar results were also found in animal 
models with renal I/R injury and ulcerative colitis [15, 
20]. Meanwhile, this study also proved that, like MSCs, 
ERCs possess immunomodulatory properties which 
could suppress the activation and proliferation of T cells 
[70].
Tregs are believed to play a critical role in the sup-
pression of both innate and adaptive immune responses 
[71], and are also an important factor in the attenuation 
of liver injury [72–74]. CD4+CD25+ Tregs account for 
5–10 % of the CD4+ T cell panel in healthy humans and 
mice, which is sufficient to maintain immune homeosta-
sis and limit autoimmune disease [75]. The role of Tregs 
in ALI has been confirmed in several studies using PC61, 
an anti-CD25 monoclonal antibody that depletes Tregs 
before liver damage, to verify the protective effect of 
Tregs. It was found that mice suffering from Treg deple-
tion experienced an aggravation of ALI compared to ALI 
mice that did not have Treg depletion [25]. In another 
study, the protective effects of Tregs on ALI were con-
firmed via the adoptive transfer method [76]. Similarly, 
our results demonstrated that CD4+CD25+Foxp3+ 
Tregs were significantly decreased in the untreated-ALI 
mice compared to the normal control mice, and sig-
nificantly elevated in ERC-treated mice, indicating that 
ERC treatment mitigated CCl4-induced acute hepato-
toxicity in mice by increasing the population of Tregs. 
Overall, we speculate that transplanted PKH26-labeled 
ERCs engraft to the spleen in mice with ALI and inter-
act with immune cells, leading to the downregulation of 
splenic CD11c+MHC-II+ DCs, CD4+ and CD8+ T cell 
population, as well as the upregulattion of Treg popula-
tion. In the meantime, since ERC supernatant could still 
exert similar beneficial effects on ALI as compared to 
the effects achieved by cell infusion (Data not shown), 
ERC treatment may also attenuate ALI by releas-
ing immunomodulatory cytokines. Experiments to better 
understand the  mechanisms of ERC-mediated immu-
nomodulation in this ALI model are underway.
Conclusions
In conclusion, our study demonstrated that human 
ERCs are effective in treating CCl4-induced ALI. ERCs 
improved liver function and attenuated pathological 
changes by promoting liver cell regeneration, modulating 
cytokine profiles, and regulating immune cells. However, 
further studies are still needed to elucidate the complex 
pathways underlying ERC-mediated liver protective 
effects at molecular levels. Taken together, these findings 
may provide a rationale for the use of ERCs in clinical 
settings.
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